scispace - formally typeset
J

Jacques D. Nguyen

Researcher at University of California, San Diego

Publications -  48
Citations -  1017

Jacques D. Nguyen is an academic researcher from University of California, San Diego. The author has contributed to research in topics: Inhalation & Oxycodone. The author has an hindex of 13, co-authored 47 publications receiving 801 citations. Previous affiliations of Jacques D. Nguyen include Scripps Health & University of North Texas Health Science Center.

Papers
More filters
Journal ArticleDOI

Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol.

TL;DR: Future cannabis-related policy decisions should include consideration of scientific findings, including the individual and interactive effects of CBD and THC, as well as other cannabinoid molecules currently being evaluated for medicinal purposes, separately and in combination.
Journal ArticleDOI

Inhaled delivery of Δ(9)-tetrahydrocannabinol (THC) to rats by e-cigarette vapor technology.

TL;DR: A rodent chamber suitable for controlled exposure to vaporized THC in a propylene glycol vehicle, using an e-cigarette delivery system adapted to standard size, sealed rat housing chambers is developed and validated.
Journal ArticleDOI

Locomotor and reinforcing effects of pentedrone, pentylone and methylone in rats.

TL;DR: The inference that second generation cathinones pentylone and pentedrone have abuse liability greater than that of methylone is supported.
Journal ArticleDOI

Effects of Δ9-THC and cannabidiol vapor inhalation in male and female rats

TL;DR: The inhalation of THC or CBD, alone and in combination, produces approximately equivalent effects in male and female rats, confirming the efficacy of the e-cigarette-based method of THC delivery in female rats.
Journal ArticleDOI

The HIV antiretroviral drug efavirenz has LSD-like properties.

TL;DR: Efavirenz’s prevailing behavioral effect in rodents is consistent with LSD-like activity mediated via the 5-HT2A receptor, and this finding correlates with the subjective experiences in humans who abuse efavirens and with specific dose-dependent adverse neuropsychiatric events, such as hallucinations and night terrors, reported by HIV patients taking it as a medication.